HoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics

• Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies
• Targets the rapidly growing global sleep clinical research market with advanced biomarker analytics and continual learning technology
• Leverages experience from clinical studies involving more than 10,000 participants to support global multicenter trials

BOSTON, July 27, 2026 /PRNewswire/ -- HoneyNaps, today announced that it has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). The registration marks a significant milestone in the company's expansion into AI-driven sleep data analytics for clinical trials and reinforces its commitment to supporting global pharmaceutical, medical device, and digital health companies with high-quality, standardized sleep analysis services.

Building on this milestone, HoneyNaps is expanding commercialization of SOMNUM Clinical, its AI-powered clinical trial analytics service. Powered by SOMNUM AI—the company's sleep analysis solution that has received two U.S. FDA clearances—SOMNUM Clinical automatically analyzes polysomnography (PSG) data and provides quantitative assessment of key sleep parameters, including sleep stages, apnea-hypopnea index (AHI), arousal events, and other clinically relevant sleep metrics. HoneyNaps combines its AI technology with extensive clinical research expertise, having supported clinical studies involving more than 10,000 participants and managed nationwide multicenter and multidisciplinary clinical trials. This integrated capability enables the company to deliver both advanced AI analytics and comprehensive clinical trial support for global research programs.

According to Dataintelo's Clinical Sleep Health Market report, the global clinical sleep health market is projected to grow from approximately USD 22.8 billion in 2025 to USD 36.9 billion by 2034. Sleep is increasingly recognized not only as a critical endpoint for sleep disorders such as insomnia and obstructive sleep apnea, but also as an important digital biomarker in clinical research involving obesity, cardiovascular disease, neurodegenerative disorders, mental health, and other therapeutic areas.

SOMNUM Clinical addresses one of the major operational challenges in sleep-related clinical trials by automating the traditionally labor-intensive analysis of polysomnography data. The platform can reduce analysis time by more than 90%, significantly improving trial efficiency while accelerating study timelines. The service applies standardized scoring criteria based on the American Academy of Sleep Medicine (AASM) guidelines, enabling objective, reproducible, and consistent sleep analysis across multiple study sites. By minimizing inter-site and inter-scorer variability, SOMNUM Clinical delivers high-quality clinical data suitable for multicenter global clinical trials.

"Sleep medicine is rapidly emerging as an important digital biomarker across a wide range of therapeutic areas, increasing the need for objective and standardized analysis in clinical research," said Sean Ha (Tae Kyoung Ha), President of HoneyNaps USA. "With our CRO registration and AI-powered analytics platform, we are expanding beyond sleep disorder studies to support clinical trials involving pharmaceuticals, wearable devices, digital therapeutics (DTx), obesity, neurological diseases, and many other healthcare innovations. Our goal is to become a global leader in AI-driven clinical trial analytics powered by digital biomarkers."

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: 14^th Floor, One Broadway, Cambridge, MA 02142, USA
Website: www.honeynaps.com

BOSTON, July 27, 2026 /PRNewswire/ -- HoneyNaps, today announced that it has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). The registration marks a significant milestone in the company's expansion into AI-driven sleep data analytics for clinical trials and reinforces its commitment to supporting global pharmaceutical, medical device, and digital health companies with high-quality, standardized sleep analysis services.

Building on this milestone, HoneyNaps is expanding commercialization of SOMNUM Clinical, its AI-powered clinical trial analytics service. Powered by SOMNUM AI—the company's sleep analysis solution that has received two U.S. FDA clearances—SOMNUM Clinical automatically analyzes polysomnography (PSG) data and provides quantitative assessment of key sleep parameters, including sleep stages, apnea-hypopnea index (AHI), arousal events, and other clinically relevant sleep metrics. HoneyNaps combines its AI technology with extensive clinical research expertise, having supported clinical studies involving more than 10,000 participants and managed nationwide multicenter and multidisciplinary clinical trials. This integrated capability enables the company to deliver both advanced AI analytics and comprehensive clinical trial support for global research programs.

According to Dataintelo's Clinical Sleep Health Market report, the global clinical sleep health market is projected to grow from approximately USD 22.8 billion in 2025 to USD 36.9 billion by 2034. Sleep is increasingly recognized not only as a critical endpoint for sleep disorders such as insomnia and obstructive sleep apnea, but also as an important digital biomarker in clinical research involving obesity, cardiovascular disease, neurodegenerative disorders, mental health, and other therapeutic areas.

SOMNUM Clinical addresses one of the major operational challenges in sleep-related clinical trials by automating the traditionally labor-intensive analysis of polysomnography data. The platform can reduce analysis time by more than 90%, significantly improving trial efficiency while accelerating study timelines. The service applies standardized scoring criteria based on the American Academy of Sleep Medicine (AASM) guidelines, enabling objective, reproducible, and consistent sleep analysis across multiple study sites. By minimizing inter-site and inter-scorer variability, SOMNUM Clinical delivers high-quality clinical data suitable for multicenter global clinical trials.

"Sleep medicine is rapidly emerging as an important digital biomarker across a wide range of therapeutic areas, increasing the need for objective and standardized analysis in clinical research," said Sean Ha (Tae Kyoung Ha), President of HoneyNaps USA. "With our CRO registration and AI-powered analytics platform, we are expanding beyond sleep disorder studies to support clinical trials involving pharmaceuticals, wearable devices, digital therapeutics (DTx), obesity, neurological diseases, and many other healthcare innovations. Our goal is to become a global leader in AI-driven clinical trial analytics powered by digital biomarkers."

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: 14^th Floor, One Broadway, Cambridge, MA 02142, USA
Website: www.honeynaps.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

HoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics

Partners with KACCWA to deploy REALIZER as the Official AI Platform for WABA Korea Expo 2026, helping businesses transform face-to-face meetings into lasting business opportunities.

SEATTLE, July 28, 2026 /PRNewswire/ -- CoBALT, an AI SaaS company specializing in business relationship intelligence, today announced its official expansion into the United States with a strategic partnership with the Korean American Chamber of Commerce of Washington State (KACCWA). Under the agreement signed on July 20, CoBALT's flagship platform, REALIZER, has been selected as the Official AI-powered Business Engagement Platform for WABA Korea Expo 2026.

Scheduled to take place in Seattle from August 14–16, 2026, with a B2B networking program beginning on August 13, WABA Korea Expo serves as a primary gateway connecting Korean and U.S. companies, investors, and industry leaders. Throughout the Expo, REALIZER will be provided to participating exhibitors to digitize, organize, and automate relationship management before, during, and after meetings.

While conventional CRM tools require manual data entry after interactions occur, REALIZER captures the full context of face-to-face meetings from the very first contact. By leveraging AI to automate contact capture, briefing preparation, and personalized follow-ups, REALIZER eliminates traditional follow-up delays — reducing response times from an industry average of 5 days to real-time execution — while boosting lead conversion rates from 47% to over 70%.

"Trade shows and B2B exhibitions are among the most critical channels for international expansion, yet companies routinely lose valuable opportunities in the days following an event due to delayed execution," said Haeil Yi, Chief Executive Officer of CoBALT. "REALIZER was built to bridge that gap. Our deployment at WABA Korea Expo demonstrates how AI can strengthen human relationships and turn initial handshakes into measurable business outcomes. This partnership marks an exciting first step in CoBALT's expansion across North America."

"WABA Korea Expo was created to build lasting bridges between businesses across Korea and the United States," said Myung Kyu Oh, President of KACCWA. "The biggest challenge for exhibitors has always been preserving relationship momentum after the event closes. Partnering with CoBALT ensures our attendees have the AI tools needed to convert meaningful conversations into long-term commercial partnerships."

Operating across major global markets — including the U.S., Singapore, Japan, South Korea, and the UAE — REALIZER has earned international recognition at premier technology forums, including GITEX Supernova and the Slingshot Global Competition.

Following WABA Korea Expo 2026, CoBALT plans to expand REALIZER across North American trade shows, industry conferences, chambers of commerce, and enterprise sales organizations.

About CoBALT

CoBALT is a global AI SaaS company developing intelligent solutions that maximize the value of in-person business interactions. Its flagship platform, REALIZER, combines AI-driven contact capture, relationship intelligence, and automated follow-up to reduce administrative burden and accelerate pipeline growth for global B2B teams. Operating from Singapore and Seoul, CoBALT serves enterprise and mid-market clients across North America, Asia, and the Middle East. For more information, visit www.realizer.ai.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CoBALT Expands to U.S. Market with AI Business Engagement Platform REALIZER